Within the CD20-CD27+ B cells population, PD-L1 and CTLA-4 were significantly downregulated in MS patients compared to HCs, indicating a reduced capacity to suppress the immune system, consistent with the known inhibitory functions of these ICs. This evidence concerns the gene CD27 and myeloid sarcoma.